Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Alone or in combination w/ MTX for active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARD therapies. Active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C-reactive protein (CRP) &/or MRI in adults who have responded inadequately to NSAIDs.
Discontinue immediately if serious hypersensitivity reaction occurs. Increased rate of infections eg, URTI, oral candidiasis, conjunctivitis, & tinea infections. Patients w/ clinically important chronic infections or a history of recurrent infection. Carefully monitor if an infection develops & discontinue use if the patient is not responding to standard therapy or if the infection becomes serious; do not resume until the infection resolves. Not to be given in patients w/ active TB; consider anti-TB therapy prior to initiation in patients w/ latent TB. Not recommended in patients w/ inflammatory bowel disease including Crohn's disease & ulcerative colitis. Not to be used w/ live vaccines. Renal or hepatic impairment. Effective contraception method during & for at least 10 wk after treatment in women of childbearing potential. Avoid use during pregnancy. Lactation. Childn ≤18 yr. Elderly ≥75 yr.
Sign Out
 80 mg_mL53085fd1-8f26-49a8-a16b-aea101262b6a.GIF)
